With effect from 1 April 2024, the founders, Saskia and Dirk Biskup, acquired all shares in cecava. The company is a spin-out of the biotechnology company CeGaT GmbH also led by the Biskups. In 2018 cecava was originally founded as a joint venture by CeGaT GmbH and the international medical technology company B. Braun. Despite many years of trusting cooperation between CeGaT and B. Braun, it was now mutually decided to terminate the cooperation as both partners will pursue different strategic directions in the future. As a consequence, B. Braun has sold its shares in cecava and CeGaT GmbH to the owner family. The parties have agreed not to disclose the purchase price.

About B. Braun
B. Braun (Melsungen, Germany) is one of the world’s leading medical technology companies. With 63,000 employees, B. Braun is a reliable partner, develops intelligent solutions and sets pioneering standards to accelerate progress in healthcare. In 2023, B. Braun generated revenues of 8.8 billion euros.

About CeGaT and cecava
CeGaT (Tübingen, Germany) is a global provider of genetic analyses for a wide range of topics in medical practice, research and the pharmaceutical industry. Founded in Tübingen in 2009, the company combines the latest sequencing technology and medical expertise with the aim of identifying the genetic causes of diseases and supporting patients and their care.

About cecava
cecava GmbH is a biopharmaceutical immuno-oncology company located in Tuebingen (Germany). Founded in 2018, cecava’s mission is to develop individualized peptide cancer therapies (INPECT). The therapy is tailored to target the patient-individual tumor mutations. Through immunizations with the AI-selected neoepitope peptides, the immune system is activated and directed against the patient’s tumor. Based on encouraging real-world experience with this novel immunotherapy, clinical trials are currently being prepared. The company’s ultimate goal is to secure the approval for this innovative treatment, ensuring that as many cancer patients as possible may benefit.